Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

Abbott Laboratories

ABTNYSEEQUITYCurrent

Other Events

Item 8.01 Other Events. As previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before the United States District Court for the Northern District of Illinois agains…

Filed Apr 17, 2026Accepted Apr 17, 2026, 4:04 PM EDTCIK 1800Accession 0001104659-26-044892
Share

Company context

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.

Current securities

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 16, 2026
  2. 10-Q filingNov 4, 2026
  3. Other EventsOct 21, 2026
  4. Results of Operations and Financial ConditionOct 21, 2026
  5. 144 filingSep 2, 2026

Registered securities in this filing

ABBOTT LABORATORIES · 8-K · Filed 2026-04-17

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Shares, Without Par Value

Symbol
ABT
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: From2026-04-102026-04-10_us-gaap_CommonStockMember_exch_XCHI

Dimensions: us-gaap:StatementClassOfStockAxis

Common Shares, Without Par Value

Symbol
ABT
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: From2026-04-102026-04-10_us-gaap_CommonStockMember_exch_XNYS

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000110465926044892 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. As previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before the United States District Court for the Northern District of Illinois against certain of Abbott’s current and former directors and officers. On April 10, 2026, in connection with that consolidated proceeding, the court signed an “Order Preliminarily Approving Proposed Settlement, Directing The Issuance Of Notice, And Setting A Final Settlement Hearing.” A copy of the Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear is filed as Exhibit 99.1.
Filed exhibits (1)
EX-99.1 (by filename) tm2611915d1_ex99-1.htm

EX-99.1 2 tm2611915d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION -------------------------------------------------------x IN RE ABBOTT LABORATORIES INFANT FORMULA SHAREHOLDER DERIVATIVE LITIGATION CASE NO: 1:22-cv-5513 Hon. Sunil R. Harjani Hon. Laura K. McNally -------------------------------------------------------x NOTICE OF PROPOSED SETTLEMENT OF CONSOLIDATED DERIVATIVE ACTION, FINAL SETTLEMENT HEARING, AND RIGHT TO APPEAR TO: ALL CURRENT HOLDERS OF ABBOTT LABORATORIES COMMON STOCK PLEASE READ THIS NOTICE CAREFULLY THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS HAS AUTHORIZED THIS NOTICE TO BE SENT TO YOU THIS IS NOT A SOLICITATION This notice (the “Notice”) advises you of the proposed settlement (the “Settlement”) of derivative claims brought against certain current and former directors and officers (“Individual Defendants”) of Abbott Laboratories (“Abbott” or the “Company”) (collectively with the Individual Defendants, “Defendants”). The parties to the Consolidated Derivative Action (as defined below), have entered into a Stipulation and …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.